Hepatitis A seroprevalence in patients with chronic hepatitis B and C at the initiation of treatment
Pamukkale Medical Journal · 13.04.2026 · 19 (2) · 385-389
DOI: 10.31362/patd.1753390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pamukkale Medical Journal, online erschienen am 13.04.2026. Verfasst von Şerife Altun Demircan und 3 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Purpose
Hepatitis A is a vaccine-preventable disease that may follow a more severe course and can lead to fulminant hepatitis in patients with chronic hepatitis. The aim of this study is to determine the seroprevalence of hepatitis A in patients with chronic hepatitis B and C, and to assess the need for hepatitis A vaccination.Materials and methods: A total of 885 adult patients with chronic hepatitis B and C, who had not previously received hepatitis A vaccination and in whom antiviral therapy was initiated between January 2008 and December 2020, were included in the study. Immunity against hepatitis A was assessed at the time of diagnosis by measuring Anti-HAV IgG using the Microparticle Enzyme Immunoassay (MEIA; AxSYM-HAVAB 2.0, ABBOTT) method.
Results
The seroprevalence of hepatitis A was 92.7% among 789 patients with chronic hepatitis B and 96 patients with chronic hepatitis C; it was determined to be 94% in patients with chronic hepatitis B and 83% in patients with chronic hepatitis C. While 78% of anti-HAV IgG seronegativity was detected in individuals under 30 years of age, 90% of seronegative cases were under 40. Seropositivity approached 100% in those over 50 years of age; however, a 64-year-old man and a 68-year-old woman with chronic hepatitis C were not immune to hepatitis A.
Conclusion
Since hepatitis A superinfection in patients with chronic hepatitis B and C may follow a severe course and lead to a fulminant course, it should be kept in mind that hepatitis A seroprevalence is low, particularly in patients under 30 years of age. However, although the rate decreases with age in adult patients, seronegativity may be detected at any age; therefore, Anti-HAV IgG should be evaluated at the time of diagnosis in all patients with chronic hepatitis, and those found to be negative should be vaccinated against hepatitis A.
Zitieren
APA
Demircan, Ş. A., Kınıklı, S., Kılıç, E. K., & Hatipoglu, C. A. (2026). Hepatitis A seroprevalence in patients with chronic hepatitis B and C at the initiation of treatment. Pamukkale Medical Journal, 19(2), 385-389. https://doi.org/10.31362/patd.1753390
Vancouver
Demircan ŞA, Kınıklı S, Kılıç EK, Hatipoglu CA. Hepatitis A seroprevalence in patients with chronic hepatitis B and C at the initiation of treatment. Pamukkale Medical Journal. 2026;19(2):385-389. doi:10.31362/patd.1753390
BibTeX
@article{Demircan2026,
author = {Demircan, Şerife Altun and Kınıklı, Sami and Kılıç, Esra Kaya and Hatipoglu, Cigdem Ataman},
title = {Hepatitis A seroprevalence in patients with chronic hepatitis B and C at the initiation of treatment},
journal = {Pamukkale Medical Journal},
year = {2026},
volume = {19},
number = {2},
pages = {385--389},
doi = {10.31362/patd.1753390}
}
EUVIMED